Apple

January 13, 2026, 7:24 AM EST. Eli Lilly and Nvidia said they will invest up to $1 billion over five years to build an AI-powered drug-discovery lab in the San Francisco Bay Area. The facility will rely on Nvidia's BioNeMo platform and its next-generation Vera Rubin computing architecture, plus robotics and other physical AI tools to move candidates from research to production faster. Nvidia CEO Jensen Huang framed life sciences as a top AI use case, while Lilly CEO David Ricks said the collaboration merges Lilly's data and science with Nvidia's computing power to unlock breakthroughs neither company could achieve alone. The deal reflects a broader shift, as pharma teams lean on AI leaders to shorten timelines and boost research efficiency.